×
Mannatech Net Current Debt 2010-2025 | MTEX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Mannatech net current debt from 2010 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
View More
Mannatech Net Current Debt 2010-2025 | MTEX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Mannatech net current debt from 2010 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$72B
Zoetis (ZTS)
$69.3B
Takeda Pharmaceutical (TAK)
$47.7B
Daiichi Sankyo, - (DSNKY)
$45.3B
BeOne Medicines - (ONC)
$33.5B
Sandoz Group AG (SDZNY)
$27.7B
Summit Therapeutics (SMMT)
$17.6B
Merck (MKKGY)
$16.4B
Shionogi (SGIOY)
$14.6B
Neurocrine Biosciences (NBIX)
$13.8B
United Therapeutics (UTHR)
$13.7B
IPSEN (IPSEY)
$11.4B
Orion OYJ (ORINY)
$11.2B
Madrigal Pharmaceuticals (MDGL)
$9.7B
Eisai (ESAIY)
$8.9B
Corcept Therapeutics (CORT)
$7.3B
Stevanato Group S.p.A (STVN)
$7B
Grifols, S.A (GRFS)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.8B
Ono Pharmaceutical (OPHLF)
$5.7B
Hikma Pharmaceuticals Plc (HKMPF)
$5.4B
Soleno Therapeutics (SLNO)
$3.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$3B
Crinetics Pharmaceuticals (CRNX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.7B
Hypermarcas (HYPMY)
$2.7B
Procaps Group, S.A (PROCF)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.2B
Ocular Therapeutix (OCUL)
$2.1B